Clinical trial results published in NEJM showed zorevunersen—an investigational gene regulation therapy for Dravet syndrome—cut seizure frequency by large margins and improved quality‑of‑life measures in pediatric patients. The multi‑dose trial across U.S. and U.K. sites reported seizure reductions ranging broadly but with median declines and functional gains that clinicians called unprecedented for this disease. Investigators emphasized safety was acceptable across dose cohorts and that phase 3 randomized studies are underway. The data signal a potential disease‑modifying option for a historically refractory pediatric epilepsy, drawing attention from rare‑disease gene‑therapy investors and pediatric neurology centers preparing for larger confirmatory trials.